Insmed Incorporated — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016. The interim financial statements are unaudited. Insmed is a clinical-stage biopharmaceutical company focused on rare diseases; its lead candidate, ARIKAYCE, was in Phase 3 development for refractory NTM lung disease and under EU regulatory review. INS1009, an inhaled treprostinil prodrug, was an earlier-stage program.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Revenue | None reported; French expanded-access revenue was immaterial and included in other income | None |
| Operating expenses | $33.1 million | $26.7 million |
| Operating loss | $33.1 million | $26.7 million |
| Net loss | $33.5 million; $0.54 per share | $27.4 million; $0.55 per share |
| Operating cash used | $29.5 million | $24.9 million |
| Cash and cash equivalents | $252.9 million | $282.9 million at Dec. 31, 2015 |
| Working capital | $232.9 million | $265.9 million at Dec. 31, 2015 |
| Debt principal | $25.0 million | $25.0 million |
No revenue base existed to assess meaningful gross margin. Debt carrying value was approximately $24.8 million, net of fees; the loan bears interest at 9.25%, with principal repayments beginning October 2016 and maturity on January 1, 2018. Total contractual obligations were $37.1 million, including debt, interest, leases, and purchase obligations.
Changes versus the comparable period
- Net loss increased $6.2 million, primarily reflecting higher clinical-development spending and increased pre-commercial and personnel costs.
- Research and development expense rose 19.7% to $20.5 million, led by CONVERT study costs and compensation; lower manufacturing expense partly offset the increase.
- General and administrative expense rose 31.2% to $12.5 million, including increased European pre-commercial activity.
- Operating cash use increased $4.6 million year over year. Cash declined $30.0 million from year-end 2015.
- Loss per share improved to $0.54 from $0.55, while weighted-average shares increased to 61.9 million from 50.0 million, reflecting the larger share base.
Outlook, risks, and contingencies
- Management said cash was sufficient for at least the next 12 months, but noted potential need for additional financing and no assurance it would be available on favorable terms. The company expected R&D and G&A expenses to increase in 2016.
- Management expected to reach its CONVERT enrollment objective in the second half of 2016. The company had submitted responses to the EMA’s 180-day list of outstanding issues, requested an oral explanation meeting expected in Q2 2016, and anticipated a CHMP opinion around mid-2016. These were forward-looking expectations, not outcomes.
- The completed Phase 2 study did not meet its prespecified primary endpoint for statistical significance (p=0.072), although a key secondary culture-conversion endpoint favored ARIKAYCE (p=0.003). The pivotal Phase 3 study was ongoing; efficacy, safety, regulatory approval, reimbursement, and commercialization remained uncertain.
- The Phase 2 report described more investigator-attributed adverse events, serious adverse events, and treatment discontinuations in the ARIKAYCE arm than placebo; two deaths during treatment were not considered drug-related by investigators.
- INS1009 Phase 1 was completed; results were expected to be presented in the second half of 2016. No later-stage development milestone was provided.
- Potential funding needs depend on clinical-trial costs, regulatory decisions, manufacturing, and launch preparation. The filing also disclosed possible milestone and royalty payments to PARI, contingent payments to Cystic Fibrosis Foundation Therapeutics if specified approvals and sales milestones occur, and estimated CONVERT and follow-on study costs of approximately $40 million and $20 million, respectively.
- The IRS was auditing the company’s 2013 federal tax return. Management did not expect ordinary-course legal matters to have a material adverse effect. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Subsequent CONVERT enrollment progress, primary-endpoint results, and any related FDA submission or review timeline.
- EMA review outcome and whether the requested oral explanation meeting changed the expected timing or scope of review.
- Cash burn, financing needs, and the company’s ability to fund trials and launch preparation beyond management’s stated 12-month horizon.
- ARIKAYCE’s safety and efficacy evidence, including the Phase 2 primary-endpoint miss and adverse-event profile, as well as confirmatory Phase 3 results.
- Debt repayment schedule beginning October 2016, maturity in January 2018, and contingent contractual payments or manufacturing commitments.